DuPontDD has developed food solutions to address the rising health concerns of Southeast Asia. The company will exhibit the solutions at Food Ingredients Asia (FIA) 2017, BITEC, Bangkok, from Sep 13-15.
Southeast Asia is prone to Type 2 diabetes and there have been reports of rising obesity also. Further consumers are shifting toward healthier and tasty foods owing to a rapid nutrition transition in the region. The company's latest move will address the health concerns of the people of this region.
DuPont's Nutrition & Health segment will exhibit solutions at the FIA for the dairy, bakery, beverage and meal solutions industries in response to health and nutrition concerns in the region.
The solutions to be introduced at FIA includes Howaru Shape, Surpo Max, Supro XT 55, PowerBake series and PowerFresh series.
Howaru Shape is a clinically proven probiotic formula that helps to reduce the circumference of the waist in overweight adults presented in a juice format. Supro Max is a high quality, structured vegetable protein that offers meat-like fibrosity and texture and can be used in red meat, poultry, fish or meat-less applications. Supro XT 55 is an isolated soy protein that enables up to 50% of dairy protein replacement in ready-to-drink beverages with excellent flavor characteristics. PowerBake series enables manufacturers to improve water absorption and yield for breads by combining the effects of cellulases and oxidases enzymes. Based on DuPont's patented G4-amylase and G+ amylase technology PowerFresh series boasts a high degree of resilience, ensuring bread retains softness throughout the shelf life.
These solutions will be featured along with other DuPont Dansico range of ingredients that are in tandem with the current health trends such as low sugar, high protein and plant-based diets. The company's experts present there will explain how these solutions can improve nutritional profile while maintaining the desired taste and texture of food products.
DuPont has outperformed the industry over the last three months. The company's shares have moved up 6.2% over this period, compared with the industry's gain of around 4.4%.
DuPont kept its positive earnings surprise streak alive with a solid beat in second-quarter 2017. The company recorded adjusted earnings of $1.38 per share in the reported quarter, up 11% from $1.24 per share a year ago. Results topped the Zacks Consensus Estimate of $1.29. DuPont logged net sales of $7,424 million, up roughly 5% year over year on higher volumes. The figure surpassed the Zacks Consensus Estimate of $$7,260 million.
DuPont is well positioned to gain from its cost-cutting and productivity improvement measures and product launches. The company has numerous new products in its pipeline that are expected to create value for customers.
Moreover, the planned mega-merger with Dow Chemical DOW is also expected to deliver cost synergies of around $3 billion and growth synergies of roughly $1 billion. The companies expect the closing of the merger to take place on Aug 31.
E.I. du Pont de Nemours and Company Price and Consensus
Zacks Rank & Other Stocks to Consider
DuPont currently carries a Zacks Rank #2 (Buy).
Other top-ranked stocks in the chemical space are BASF SE BASFY and The Chemours Company CC . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
BASF has an expected long-term earnings growth of 8.6%.
Chemours has an expected long-term earnings growth of 15.5%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.